Mdverse
MDVerse: Innovating regenerative medicine and drug development with disruptive software solutions.
Founded
2022MDVerse: Innovating regenerative medicine and drug development with disruptive software solutions.
Founded with the mission to revolutionize regenerative medicine, MDVerse focuses on developing innovative software solutions for drug development, manufacturing, and clinical trials. The company's vision is to expedite the delivery of personalized, precision therapies by leveraging disruptive technologies. MDVerse serves pharmaceutical companies, academic institutions, and clinical sites, offering next-generation software, analytics, and generative AI to enhance the efficiency and effectiveness of therapeutic development.
Notable figures associated with MDVerse include leading experts in regenerative medicine and AI technology. The company has secured investments from prominent venture capital firms specializing in biotech and healthcare innovation. Key achievements include successful collaborations with top-tier pharmaceutical companies and academic institutions, accelerating the timeline for clinical trials and drug manufacturing. MDVerse's impact is evident in its contribution to faster and more efficient development of personalized therapies, positioning it as a pivotal player in the biotech industry.
Companies similar to Mdverse include BioVeras, Regenerative Bio, Cipherome and Qrativ.
Mdverse was founded in 2022.
Mdverse's headquarters is located in Incline Village, NV, US.
Mdverse's most recent funding round was for $750k (USD) in January 2023.
As of Jan 1, 2023, Mdverse has disclosed funding of $750k (USD). Undisclosed round amounts are excluded.
Mdverse has 6 employees as of Feb 5, 2024.
Qrativ
qrativ.bio
